Zimmer Biomet Holdings Stock Performance
| ZBH Stock | USD 112.02 1.38 1.25% |
The firm maintains a market beta of 0.56, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Zimmer Biomet's returns are expected to increase less than the market. However, during the bear market, the loss of holding Zimmer Biomet is expected to be smaller as well. At this point, Zimmer Biomet Holdings has a negative expected return of -0.0293%. Please make sure to check out Zimmer Biomet's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Zimmer Biomet Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zimmer Biomet Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental drivers, Zimmer Biomet is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 1.25 | Five Day Return 3.08 | Year To Date Return (7.72) | Ten Year Return 2.83 | All Time Return 288.02 |
Forward Dividend Yield 0.0086 | Payout Ratio 0.1217 | Last Split Factor 103:100 | Forward Dividend Rate 0.96 | Dividend Date 2024-10-31 |
1 | Acquisition by Kurdikar Devdatt of 127 shares of Zimmer Biomet at 107.76 subject to Rule 16b-3 | 09/30/2024 |
2 | Fluid Management Systems Industry Report 2024 Global, Regional and Country-level Analysis by Product, Disposables Accessories, Application and End-user - A 47 B... | 10/09/2024 |
3 | Bernzott Capital Advisors Has 4.32 Million Position in Zimmer Biomet Holdings, Inc. | 10/29/2024 |
| Zimmer Biomet dividend paid on 31st of October 2024 | 10/31/2024 |
5 | Asia Pacific Bone Cement Market Forecast Report 2024-2032 - Shift Towards Antibiotic-Loaded Bone Cement, Adoption of Biodegradable Bone Cements and Customised S... | 11/05/2024 |
6 | Health Check Prestigious publication supports Alteritys iron overload in brain thesis | 11/06/2024 |
7 | Acquisition by Suketu Upadhyay of 15948 shares of Zimmer Biomet subject to Rule 16b-3 | 11/08/2024 |
8 | Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3 | 11/12/2024 |
9 | Zimmer Biomets SWOT analysis stock outlook amid ERP challenges, growth plans | 11/13/2024 |
10 | Zimmer Biomet wins CE mark for Persona Knee | 11/18/2024 |
11 | Zimmer Biomet to Present at Citis 2024 Global Healthcare Conference | 11/21/2024 |
12 | Studio Investment Management LLC Increases Position in Zimmer Biomet Holdings, Inc. | 11/22/2024 |
13 | Zimmer gets FDA approval for Oxford Cementless Partial Knee implant | 11/25/2024 |
14 | Zimmer Biomet wins FDA nod for cementless partial knee | 11/26/2024 |
| Begin Period Cash Flow | 375.7 M |
Zimmer |
Zimmer Biomet Relative Risk vs. Return Landscape
If you would invest 11,520 in Zimmer Biomet Holdings on August 30, 2024 and sell it today you would lose (318.00) from holding Zimmer Biomet Holdings or give up 2.76% of portfolio value over 90 days. Zimmer Biomet Holdings is generating negative expected returns assuming volatility of 1.6979% on return distribution over 90 days investment horizon. In other words, 15% of stocks are less volatile than Zimmer, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Zimmer Biomet Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zimmer Biomet's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zimmer Biomet Holdings, and traders can use it to determine the average amount a Zimmer Biomet's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0172
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZBH |
Estimated Market Risk
| 1.7 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zimmer Biomet is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zimmer Biomet by adding Zimmer Biomet to a well-diversified portfolio.
Zimmer Biomet Fundamentals Growth
Zimmer Stock prices reflect investors' perceptions of the future prospects and financial health of Zimmer Biomet, and Zimmer Biomet fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zimmer Stock performance.
| Return On Equity | 0.0871 | ||||
| Return On Asset | 0.0461 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 28.3 B | ||||
| Shares Outstanding | 199.07 M | ||||
| Price To Earning | 77.41 X | ||||
| Price To Book | 1.80 X | ||||
| Price To Sales | 2.94 X | ||||
| Revenue | 7.39 B | ||||
| Gross Profit | 4.92 B | ||||
| EBITDA | 2.21 B | ||||
| Net Income | 1.02 B | ||||
| Cash And Equivalents | 375.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 6 B | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 62.00 X | ||||
| Cash Flow From Operations | 1.58 B | ||||
| Earnings Per Share | 5.24 X | ||||
| Market Capitalization | 22.3 B | ||||
| Total Asset | 21.5 B | ||||
| Retained Earnings | 10.38 B | ||||
| Working Capital | 1.75 B | ||||
| Current Asset | 5.85 B | ||||
| Current Liabilities | 1.62 B | ||||
About Zimmer Biomet Performance
By evaluating Zimmer Biomet's fundamental ratios, stakeholders can gain valuable insights into Zimmer Biomet's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zimmer Biomet has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zimmer Biomet has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 417.79 | 261.70 | |
| Return On Tangible Assets | 0.13 | 0.18 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.05 | 0.05 | |
| Return On Equity | 0.08 | 0.08 |
Things to note about Zimmer Biomet Holdings performance evaluation
Checking the ongoing alerts about Zimmer Biomet for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zimmer Biomet Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zimmer Biomet generated a negative expected return over the last 90 days | |
| Over 93.0% of the company outstanding shares are owned by institutional investors | |
| On 31st of October 2024 Zimmer Biomet paid $ 0.24 per share dividend to its current shareholders | |
| Latest headline from massdevice.com: Zimmer Biomet wins FDA nod for cementless partial knee |
- Analyzing Zimmer Biomet's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zimmer Biomet's stock is overvalued or undervalued compared to its peers.
- Examining Zimmer Biomet's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zimmer Biomet's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zimmer Biomet's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zimmer Biomet's stock. These opinions can provide insight into Zimmer Biomet's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |